<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38932253</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>14</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Application of MPBT Assay for Multiplex Determination of Infectious Titers and for Selection of the Optimal Formulation for the Trivalent Novel Oral Poliovirus Vaccine.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">961</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16060961</ELocationID><Abstract><AbstractText>Recently, a multiplex PCR-based titration (MPBT) assay was developed for simultaneous determination of infectious titers of all three Sabin strains of the oral poliovirus vaccine (OPV) to replace the conventional CCID<sub>50</sub> assay, which is both time-consuming and laborious. The MPBT assay was shown to be reproducible, robust and sensitive. The conventional and MPBT assays showed similar results and sensitivity. The MPBT assay can be completed in two to three days, instead of ten days for the conventional assay. To prevent attenuated vaccine strains of poliovirus from reversion to virulence, a novel, genetically stable OPV (nOPV) was developed by modifying the genomes of conventional Sabin strains used in OPV. In this work, we evaluated the MPBT assay as a rapid screening tool to support trivalent nOPV (tnOPV) formulation development by simultaneous titration of the three nOPV strains to confirm stability as needed, for the selection of the lead tnOPV formulation candidate. We first assessed the ability of the MPBT assay to discriminate a 0.5 log<sub>10</sub> titer difference by titrating the two tnOPV samples (undiluted and threefold-diluted) on the same plate. Once the assay was shown to be discriminating, we then tested different formulations of tnOPV drug products (DPs) that were subjected to different exposure times at 37 °C (untreated group and treated groups: 2 and 7 days at 37 °C), and to three freeze and thaw (FT) cycles. Final confirmation of the down selected formulation candidates was achieved by performing the conventional CCID<sub>50</sub> assay, comparing the stability of untreated and treated groups and FT stability testing on the top three candidates. The results showed that the MPBT assay generates similar titers as the conventional assay. By testing two trivalent samples in the same plate, the assay can differentiate a 0.5 log<sub>10</sub> difference between the titers of the tested nOPV samples. Also, the assay was able to detect the gradual degradation of nOPV viruses with different formulation compositions and under different time/temperature conditions and freeze/thaw cycles. We found that there were three tnOPV formulations which met the stability criteria of less than 0.5 log<sub>10</sub> loss after 2 days' exposure to 37 ℃ and after three FT cycles, maintaining the potency of all three serotypes in these formulations. The ability of the MPBT assay to titrate two tnOPV lots (six viruses) in the same plate makes it cheaper and gives it a higher throughput for rapid screening. The assay detected the gradual degradation of the tnOPV and was successful in the selection of optimal formulations for the tnOPV. The results demonstrated that the MPBT method can be used as a stability indicating assay to assess the thermal stability of the nOPV. It can be used for rapid virus titer determination during the vaccine manufacturing process, and in clinical trials. The MPBT assay can be automated and applied for other viruses, including those with no cytopathic effect.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Manukyan</LastName><ForeName>Hasmik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lal</LastName><ForeName>Manjari</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3574-9989</Identifier><AffiliationInfo><Affiliation>Center for Vaccine Innovation and Access, Program for Appropriate Technology in Health (PATH), Seattle, WA 98121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Changcheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation and Access, Program for Appropriate Technology in Health (PATH), Seattle, WA 98121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Tsai-Lien</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tritama</LastName><ForeName>Erman</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Research and Development Division, PT Bio Farma, Bandung 40161, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chumakov</LastName><ForeName>Konstantin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Shwu-Maan</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0003-0819-0569</Identifier><AffiliationInfo><Affiliation>Center for Vaccine Innovation and Access, Program for Appropriate Technology in Health (PATH), Seattle, WA 98121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laassri</LastName><ForeName>Majid</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0110-5504</Identifier><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>INV-022260</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>Investment ID INV-022260</GrantID><Agency>This work was partially supported by funding from the Gates Foundation</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="Y">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060885" MajorTopicYN="Y">Multiplex Polymerase Chain Reaction</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OPV</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">multiplex titration</Keyword><Keyword MajorTopicYN="N">nOPV</Keyword><Keyword MajorTopicYN="N">poliovirus surveillance</Keyword><Keyword MajorTopicYN="N">thermal stability</Keyword><Keyword MajorTopicYN="N">vaccine formulation</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>1</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38932253</ArticleId><ArticleId IdType="pmc">PMC11209357</ArticleId><ArticleId IdType="doi">10.3390/v16060961</ArticleId><ArticleId IdType="pii">v16060961</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu B. Universal PCR Primers Are Critical for Direct Sequencing-Based Enterovirus Genotyping. J. Clin. Microbiol. 2017;55:339–340. doi: 10.1128/JCM.01801-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01801-16</ArticleId><ArticleId IdType="pmc">PMC5228251</ArticleId><ArticleId IdType="pubmed">28031445</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapparel C., Siegrist F., Petty T.J., Kaiser L. Picornavirus and enterovirus diversity with associated human diseases. Infect. Genet. Evol. 2013;14:282–293. doi: 10.1016/j.meegid.2012.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2012.10.016</ArticleId><ArticleId IdType="pubmed">23201849</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Global Eradication of Wild Poliovirus Type 2 Declared. WHO; Geneva, Switzerland: 2016. Declaration Further Milestone for Globally-Coordinated Vaccineswitch in 2016 [cited 2015 Sep 20]</Citation></Reference><Reference><Citation>WHO . Two Out of Three Wild Poliovirus Strains Eradicated. WHO; Geneva, Switzerland: 2019. Globaleradication of Wild Poliovirus Type 3 Declared on World Polio Day 2019.</Citation></Reference><Reference><Citation>Laassri M., Lottenbach K., Belshe R., Rennels M., Plotkin S., Chumakov K. Analysis of reversions in the 5′-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. J. Infect. Dis. 2006;193:1344–1349. doi: 10.1086/503366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/503366</ArticleId><ArticleId IdType="pubmed">16619180</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakovenko M.L., Korotkova E.A., Ivanova O.E., Eremeeva T.P., Samoilovich E., Uhova I., Gavrilin G.V., Agol V.I. Evolution of the Sabin vaccine into pathogenic derivatives without appreciable changes in antigenic properties: need for improvement of current poliovirus surveillance. J. Virol. 2009;83:3402–3406. doi: 10.1128/JVI.02122-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02122-08</ArticleId><ArticleId IdType="pmc">PMC2655595</ArticleId><ArticleId IdType="pubmed">19129444</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Detection of Circulating Vaccine Derived Polio Virus 2 (cVDPV2) in Environmental Samples—The United Kingdom of Great Britain and Northern Ireland and the United States of America. WHO; Geneva, Switzerland: 2022.</Citation></Reference><Reference><Citation>Konopka-Anstadt J.L., Campagnoli R., Vincent A., Shaw J., Wei L., Wynn N.T., Smithee S.E., Bujaki E., Te Yeh M., Laassri M., et al. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines. 2020;5:26. doi: 10.1038/s41541-020-0176-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-020-0176-7</ArticleId><ArticleId IdType="pmc">PMC7083942</ArticleId><ArticleId IdType="pubmed">32218998</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh M.T., Bujaki E., Dolan P.T., Smith M., Wahid R., Konz J., Weiner A.J., Bandyopadhyay A.S., Van Damme P., De Coster I., et al. Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence. Cell Host Microbe. 2020;27:736–751.e8. doi: 10.1016/j.chom.2020.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Macadam A.J., Ferguson G., Stone D.M., Meredith J., Knowlson S., Auda G., Almond J.W., Minor P.D. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: Relevance to poliomyelitis eradication. J. Virol. 2006;80:8653–8663. doi: 10.1128/JVI.00370-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00370-06</ArticleId><ArticleId IdType="pmc">PMC1563845</ArticleId><ArticleId IdType="pubmed">16912313</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns C.C., Campagnoli R., Shaw J., Vincent A., Jorba J., Kew O. Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons. J. Virol. 2009;83:9957–9969. doi: 10.1128/JVI.00508-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00508-09</ArticleId><ArticleId IdType="pmc">PMC2747992</ArticleId><ArticleId IdType="pubmed">19605476</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay A.S., Cooper L.V., Zipursky S. One billion doses and WHO prequalification of nOPV2: Implications for the global polio situation and beyond. PLOS Glob. Public Health. 2024;4:e0002920. doi: 10.1371/journal.pgph.0002920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgph.0002920</ArticleId><ArticleId IdType="pmc">PMC10857585</ArticleId><ArticleId IdType="pubmed">38335217</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Meeting of Strategic Advisory Group of Experts on Immunization, October 2021: Conclusions and recommendations. Wkly. Epidemiol. Rec. 2021;50:613–632.</Citation></Reference><Reference><Citation>Yeh M.T., Smith M., Carlyle S., Konopka-Anstadt J.L., Burns C.C., Konz J., Andino R., Macadam A. Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3. Nature. 2023;619:135–142. doi: 10.1038/s41586-023-06212-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06212-3</ArticleId><ArticleId IdType="pmc">PMC10322712</ArticleId><ArticleId IdType="pubmed">37316671</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht P., Enterline J.C., Boone E.J., Klutch M.J. Poliovirus and polio antibody assay in HEp-2 and Vero cell cultures. J. Biol. Stand. 1983;11:91–97. doi: 10.1016/S0092-1157(83)80031-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-1157(83)80031-6</ArticleId><ArticleId IdType="pubmed">6306012</ArticleId></ArticleIdList></Reference><Reference><Citation>Bey E., Golombick T. A comparison of three methods for titration of poliovirus vaccines. J. Virol. Methods. 1984;9:123–130. doi: 10.1016/0166-0934(84)90004-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-0934(84)90004-1</ArticleId><ArticleId IdType="pubmed">6096387</ArticleId></ArticleIdList></Reference><Reference><Citation>Magrath D.I., Seagroatt V. The standardization of infectivity titrations of poliovaccines—A WHO collaborative study. J. Biol. Stand. 1985;13:159–166. doi: 10.1016/S0092-1157(85)80022-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-1157(85)80022-6</ArticleId><ArticleId IdType="pubmed">3997898</ArticleId></ArticleIdList></Reference><Reference><Citation>Manukyan H., Rodionova E., Zagorodnyaya T., Lin T.L., Chumakov K., Laassri M. Multiplex PCR-based titration (MPBT) assay for determination of infectious titers of the three Sabin strains of live poliovirus vaccine. Virol. J. 2019;16:122. doi: 10.1186/s12985-019-1233-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-019-1233-6</ArticleId><ArticleId IdType="pmc">PMC6819588</ArticleId><ArticleId IdType="pubmed">31660997</ArticleId></ArticleIdList></Reference><Reference><Citation>Manukyan H., Zagorodnyaya T., Ruttimann R., Manor Y., Bandyopadhyay A., Shulman L., Chumakov K., Laassri M. Quantitative multiplex one-step RT-PCR assay for identification and quantitation of Sabin strains of poliovirus in clinical and environmental specimens. J. Virol. Methods. 2018;259:74–80. doi: 10.1016/j.jviromet.2018.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2018.06.009</ArticleId><ArticleId IdType="pubmed">29920299</ArticleId></ArticleIdList></Reference><Reference><Citation>Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch. Exp. Pathol. Pharmakol. 1931;162:480–483. doi: 10.1007/BF01863914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01863914</ArticleId></ArticleIdList></Reference><Reference><Citation>Chocarro L.B., Manau M.V. Test of the potency of trivalent oral polio vaccines: Comparison of 2 methods of reading. Rev. Argent. Microbiol. 1987;19:65–69.</Citation><ArticleIdList><ArticleId IdType="pubmed">2459727</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Recommendations to Assure the Quality, Safety and Efficacy of Poliomyelitis Vaccines (Oral, Live, Attenuated), Annex 2, TRS No 1045. WHO; Geneva, Switzerland: 2023.</Citation></Reference><Reference><Citation>Manukyan H., Tritama E., Wahid R., Anstadt J., Konz J., Chumakov K., Laassri M. Improvement of the qmosRT-PCR Assay and Its Application for the Detection and Quantitation of the Three Serotypes of the Novel Oral Polio Vaccine in Stool Samples. Vaccines. 2023;11:1729. doi: 10.3390/vaccines11111729.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11111729</ArticleId><ArticleId IdType="pmc">PMC10675353</ArticleId><ArticleId IdType="pubmed">38006061</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Polio Laboratory Manual. 4th ed. World Health Organization; Geneva, Switzerland: 2004.</Citation></Reference><Reference><Citation>Ecarma M.J.Y., Nolden A.A. A review of the flavor profile of metal salts: Understanding the complexity of metallic sensation. Chem. Senses. 2021;46:bjab043. doi: 10.1093/chemse/bjab043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/chemse/bjab043</ArticleId><ArticleId IdType="pubmed">34498058</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zajac A.L., Lei W., Christensen C.M., Margolskee R.F., Bouysset C., Golebiowski J., Zhao H., Fiorucci S., Jiang P. Metal Ions Activate the Human Taste Receptor TAS2R7. Chem. Senses. 2019;44:339–347. doi: 10.1093/chemse/bjz024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/chemse/bjz024</ArticleId><ArticleId IdType="pmc">PMC6538953</ArticleId><ArticleId IdType="pubmed">31066447</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper L.A., Scott T.W. Differential evolution of eastern equine encephalitis virus populations in response to host cell type. Genetics. 2001;157:1403–1412. doi: 10.1093/genetics/157.4.1403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/genetics/157.4.1403</ArticleId><ArticleId IdType="pmc">PMC1461603</ArticleId><ArticleId IdType="pubmed">11290699</ArticleId></ArticleIdList></Reference><Reference><Citation>LaBarre D.D., Lowy R.J. Improvements in methods for calculating virus titer estimates from TCID50 and plaque assays. J. Virol. Methods. 2001;96:107–126. doi: 10.1016/S0166-0934(01)00316-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-0934(01)00316-0</ArticleId><ArticleId IdType="pubmed">11445142</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.Y., Kam Y.W., Fric J., Malleret B., Koh E.G., Prakash C., Huang W., Lee W.W., Lin C., Lin R.T., et al. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. PLoS Pathog. 2011;7:e1002390. doi: 10.1371/journal.ppat.1002390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002390</ArticleId><ArticleId IdType="pmc">PMC3228792</ArticleId><ArticleId IdType="pubmed">22144891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Bueno A., Mateu M.G., Almendral J.M. High mutant frequency in populations of a DNA virus allows evasion from antibody therapy in an immunodeficient host. J. Virol. 2003;77:2701–2708. doi: 10.1128/JVI.77.4.2701-2708.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.4.2701-2708.2003</ArticleId><ArticleId IdType="pmc">PMC141124</ArticleId><ArticleId IdType="pubmed">12552010</ArticleId></ArticleIdList></Reference><Reference><Citation>Takenaka A., Gibbs C.J., Jr., Gajdusek D.C. Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique. Arch. Virol. 1985;84:197–206. doi: 10.1007/BF01378972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01378972</ArticleId><ArticleId IdType="pubmed">2859845</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B.M., Mulkey S.B., Campos J.M., DeBiasi R.L. Laboratory diagnosis of CNS infections in children due to emerging and re-emerging neurotropic viruses. Pediatr. Res. 2024;95:543–550. doi: 10.1038/s41390-023-02930-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41390-023-02930-6</ArticleId><ArticleId IdType="pubmed">38042947</ArticleId></ArticleIdList></Reference><Reference><Citation>Roldao A., Oliveira R., Carrondo M.J., Alves P.M. Error assessment in recombinant baculovirus titration: Evaluation of different methods. J. Virol. Methods. 2009;159:69–80. doi: 10.1016/j.jviromet.2009.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2009.03.007</ArticleId><ArticleId IdType="pubmed">19442848</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin J., Burns C.C., Jorba J., Shulman L.M., Macadam A., Klapsa D., Majumdar M., Bullows J., Frolov A., Mate R., et al. Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing-Worldwide, March-October 2021. MMWR Morb. Mortal. Wkly. Rep. 2022;71:786–790. doi: 10.15585/mmwr.mm7124a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7124a2</ArticleId><ArticleId IdType="pubmed">35709073</ArticleId></ArticleIdList></Reference><Reference><Citation>Bivalent Poliomyelitis Vaccine Type 1 &amp; Type 3, Live (Oral) [Packaging Insert] Bulk Source: PT; Biofarma; Bandung, Indonesia: 2019.</Citation></Reference><Reference><Citation>WHO . Polio Vaccines: WHO Position Paper. WHO; Geneva, Switzerland: 2016.</Citation></Reference><Reference><Citation>Liu B., Forman M., Valsamakis A. Optimization and evaluation of a novel real-time RT-PCR test for detection of parechovirus in cerebrospinal fluid. J. Virol. Methods. 2019;272:113690. doi: 10.1016/j.jviromet.2019.113690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2019.113690</ArticleId><ArticleId IdType="pubmed">31283959</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>